Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPV vs fIPV Immunogenicity in Infants
NCT03890497Phase 4Unknown
- Sponsor
- icddr,b
- Start
- Sep 2018
- Primary completion
- Sep 2022
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of trivalent inactivated polio vaccine in poliomyelitis (2 arms), sponsored by icddr,b. Primary endpoint: Seroconversion to Poliovirus Type 2 at 2 months. Status: unknown.
02
Drugs
trivalent inactivated polio vaccine
03
Conditions
poliomyelitis
Beyond the preview
Go deeper on NCT03890497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03890497.